A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer

HPV vaccine: Cervarix

(2010) Anne Szarewski   EXPERT OPINION ON BIOLOGICAL THERAPY

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years

(2009)   LANCET

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

(2009) J Paavonen et al.   LANCET

Effectiveness and Cost Effectiveness of Human Papillomavirus Vaccine

(2009) Fawziah Marra et al.   PHARMACOECONOMICS

Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France

(2008) Christine Bergeron et al.   INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE

Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination

(2008) Donna Debicki et al.   VACCINE

Modeling Cervical Cancer Prevention in Developed Countries

(2008) Jane J. Kim et al.   VACCINE

Cost-effectiveness of vaccination against cervical cancer: A multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios

(2008) Eugenio Suárez et al.   VACCINE

Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: A multi-regional health economic analysis

(2008) Raina M. Rogoza et al.   VACCINE